目前的T细胞参与者在固体癌症的早期临床开发中的现状
Andrea Spinazzola1, Giovanni Maria Iannantuono1, James L Gulley2
1Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di ricovero e cura a carattere scientifico (IRCCS), Rome, Italy.
Frontiers in immunology
|October 22, 2025
概括
T细胞参与剂 (TCE) 是一种新型免疫疗法,它将T细胞与癌细胞联系起来,以进行向破坏. 虽然固体瘤仍然面临挑战,但早期试验显示这些创新的癌症治疗方法具有有希望的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- T细胞参与剂 (TCE) 是一种有前途的免疫疗法药物.
- 这些药物被设计为T淋巴细胞和瘤细胞的桥梁,启动免疫突触.
- 这种相互作用促进了强大的,免疫媒介的瘤细胞破坏.
研究的目的:
- 对实体瘤的早期临床开发中TCEs的现状进行审查.
- 描述与TCEs相关的作用机制,临床进展,疗效和挑战.
- 提供关于TCEs在固体瘤治疗中的未来潜力的见解.
主要方法:
- 对涉及TCE用于固体瘤的早期临床试验的文献综述.
- 对TCE机制,疗效和安全性发表的数据的分析.
- 综合有关技术进步和TCE开发中的挑战信息.
主要成果:
- 几种TCE候选药物正在实体瘤的早期临床试验中.
- 在一些试验中观察到令人鼓舞的疗效迹象.
- 尽管取得了进展,但固体瘤的临床活动仍然是一个需要改进的领域.
结论:
- 在固体瘤的治疗中,TCE具有显著的潜力.
- 持续的研究和技术进步对于克服当前挑战至关重要.
- 进一步的临床开发是必要的,以充分实现TCEs在瘤学的治疗益处.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
T Cell Activation and Clonal Selection
14.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


